Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Francesco Maria Guida"'
Autor:
Matteo Conti, Elena Bolzacchini, Giovanna Luchena, Lorenza Bertu’, Paola Tagliabue, Stefania Aglione, Antonio Ardizzoia, Jessica Arnoffi, Francesco Maria Guida, Alessandro Bertolini, Alessandro Pastorini, Maria Duro, Donato Bettega, Giovambattista Roda’, Salvatore Artale, Alessandro Squizzato, Monica Giordano
Publikováno v:
Cancers, Vol 15, Iss 13, p 3465 (2023)
Trifluridine/tipiracil (TAS-102) is an oral chemotherapy approved for the treatment of metastatic colorectal cancer. The efficacy and tolerability of TAS-102 were shown in phase II-III clinical trials and in several real-life studies. The elderly and
Externí odkaz:
https://doaj.org/article/ff18136f2da041bcb6edd522230eaea5
Autor:
Francesco Pantano, Matteo Santoni, Giuseppe Procopio, Mimma Rizzo, Roberto Iacovelli, Camillo Porta, Alessandro Conti, Antonio Lugini, Michele Milella, Luca Galli, Cinzia Ortega, Francesco Maria Guida, Marianna Silletta, Giovanni Schinzari, Elena Verzoni, Daniela Modica, Pierfilippo Crucitti, Annamaria Rauco, Alessandra Felici, Valentina Ballatore, Stefano Cascinu, Giuseppe Tonini, Giacomo Carteni, Antonio Russo, Daniele Santini
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0120427 (2015)
Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum chol
Externí odkaz:
https://doaj.org/article/0ead798f347c420a8b9a691e710c04be
Autor:
Daniele Santini, Francesco Pantano, Ferdinando Riccardi, Giovan Giuseppe Di Costanzo, Raffaele Addeo, Francesco Maria Guida, Mariella Spalato Ceruso, Sandro Barni, Paola Bertocchi, Sara Marinelli, Paolo Marchetti, Antonio Russo, Mario Scartozzi, Luca Faloppi, Matteo Santoni, Stefano Cascinu, Evaristo Maiello, Franco Silvestris, Marco Tucci, Toni Ibrahim, Gianluca Masi, Antonio Gnoni, Alessandro Comandone, Nicola Fazio, Alessandro Conti, Ilaria Imarisio, Salvatore Pisconti, Elisa Giommoni, Saverio Cinieri, Vincenzo Catalano, Vincenzo Ostilio Palmieri, Giovanni Infante, Michele Aieta, Antonio Trogu, Cosmo Damiano Gadaleta, Anna Elisabetta Brunetti, Vito Lorusso, Nicola Silvestris
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e105268 (2014)
BackgroundBone is an uncommon site of metastasis in patients with advanced hepatocellular carcinoma (HCC). Therefore, there are few studies concerning the natural history of bone metastasis in patients with HCC.Patients and methodsData on clinicopath
Externí odkaz:
https://doaj.org/article/22b1351a79dc44dc810a7ab49dc4f62f
Autor:
Giordano, Matteo Conti, Elena Bolzacchini, Giovanna Luchena, Lorenza Bertu’, Paola Tagliabue, Stefania Aglione, Antonio Ardizzoia, Jessica Arnoffi, Francesco Maria Guida, Alessandro Bertolini, Alessandro Pastorini, Maria Duro, Donato Bettega, Giovambattista Roda’, Salvatore Artale, Alessandro Squizzato, Monica
Publikováno v:
Cancers; Volume 15; Issue 13; Pages: 3465
Trifluridine/tipiracil (TAS-102) is an oral chemotherapy approved for the treatment of metastatic colorectal cancer. The efficacy and tolerability of TAS-102 were shown in phase II-III clinical trials and in several real-life studies. The elderly and
Autor:
Giannantonio Spena, Francesco Maria Guida, Carlo Ferrarese, Giuseppe De Nobili, Andrea Rigamonti, Andrea Salmaggi, Nicola Rifino
Publikováno v:
Journal of the neurological sciences. 405
Autor:
Emanuela Dell'Aquila, Giuseppe Perrone, Marco Caricato, Bruno Vincenzi, Michelina Amato, Francesco Pantano, Francesco Maria Guida, Francesco Graziano, Antonio Russo, Vincenzo Catalano, Daniele Santini, Daniela Righi, Giuseppe Tonini, Andrea Onetti Muda, Sergio Rizzo, Pierpaolo Berti
Publikováno v:
Journal of Cellular and Molecular Medicine
Tumour-associated Macrophages (TAM) present two different polarizations: classical (M1) characterized by immunostimulation activity and tumour suppression; alternative (M2) characterized by tumour promotion and immune suppression. In this retrospecti
Autor:
Pierpaolo Berti, Gaia Schiavon, Marco Imperatori, Giuseppe Tonini, Bruno Vincenzi, Daniele Santini, Olga Venditti, Anna Maria Frezza, Francesco Maria Guida
Publikováno v:
Lancet Oncology, 13(10), 1020-1024. Lancet Publishing Group
Itch is a common side-effect of treatment with anti-EGFR antibodies and tyrosine-kinase inhibitors. We designed a pilot single-centre study to assess the effects of aprepitant-a neurokinin receptor inhibitor-for management of severe pruritus induced
Autor:
Marco Russano, Francesco Maria Guida, Giuseppe Tonini, Raffaele Ratta, Olga Venditti, Bruno Vincenzi, Daniele Santini, Loretta D'Onofrio
Publikováno v:
BMC Research Notes
Background Pazopanib is an oral multitargeted tyrosine-kinase inhibitor, used as a single agent to treat advanced renal cell carcinoma. Treatment with other tyrosine-kinase inhibitors is known to be associated with asymptomatic elevations of serum am
Autor:
Nicola Silvestris, Toni Ibrahim, Cosmo Damiano Gadaleta, Francesco Maria Guida, Giovanni Infante, Marco Tucci, Vincenzo Catalano, Evaristo Maiello, Vincenzo Palmieri, Anna Elisabetta Brunetti, Vito Lorusso, Raffaele Addeo, Daniele Santini, Ferdinando Riccardi, Alessandro Comandone, Antonio Russo, Mario Scartozzi, Sandro Barni, Nicola Fazio, Michele Aieta, Gianluca Masi, Paola Bertocchi, Antonio Trogu, Sara Marinelli, Antonio Gnoni, Ilaria Imarisio, Elisa Giommoni, Francesco Pantano, Mariella Spalato Ceruso, Saverio Cinieri, Stefano Cascinu, Alessandro Conti, Franco Silvestris, Giovan Giuseppe Di Costanzo, Paolo Marchetti, Matteo Santoni, Luca Faloppi, Salvatore Pisconti
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e105268 (2014)
PLoS ONE
PLoS ONE
BackgroundBone is an uncommon site of metastasis in patients with advanced hepatocellular carcinoma (HCC). Therefore, there are few studies concerning the natural history of bone metastasis in patients with HCC.Patients and methodsData on clinicopath
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca34e89789c3ae77614325ce13011e17
http://hdl.handle.net/10447/104480
http://hdl.handle.net/10447/104480
Autor:
Marianna Silletta, Annamaria Rauco, Alessandra Felici, Antonio Russo, Luca Galli, Giuseppe Procopio, Antonio Lugini, Elena Verzoni, Daniele Santini, Pierfilippo Crucitti, Alessandro Conti, Mimma Rizzo, Daniela Modica, Stefano Cascinu, Giuseppe Tonini, Camillo Porta, Giacomo Cartenì, Cinzia Ortega, Francesco Pantano, Roberto Iacovelli, Valentina Ballatore, Giovanni Schinzari, Matteo Santoni, Michele Milella, Francesco Maria Guida
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 4, p e0120427 (2015)
PLoS ONE, Vol 10, Iss 4, p e0120427 (2015)
Background: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of tota